TGBA01AD

TGBA01AD
Clinical data
Other namesFKB01MD
Routes of
administration
By mouth
Pharmacokinetic data
Bioavailability17%
Elimination half-life4 hours

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder. It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.